Racz Jennifer M, Degnim Amy C
Department of Surgery, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
Department of Surgery, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
Surg Oncol Clin N Am. 2018 Jan;27(1):23-32. doi: 10.1016/j.soc.2017.07.011.
Atypical ductal hyperplasia (ADH) is a proliferative, nonobligate precursor breast lesion and a marker of increased risk for breast carcinoma. Surgical excision remains the standard recommendation following a core needle biopsy result consistent with ADH. Recent research suggests that women with no mass lesion or discordance, removal of greater than or equal to 90% of calcifications at the time of core needle biopsy, involvement of less than or equal to 2 terminal duct lobular units, and absence of cytologic atypia or necrosis are likely to have a less than 5% chance of a missed cancer.
非典型导管增生（ADH）是一种增殖性、非必然发展的乳腺前驱病变，也是乳腺癌风险增加的一个标志物。在粗针活检结果符合ADH后，手术切除仍是标准的推荐治疗方法。最近的研究表明，对于没有肿块病变或不一致情况、在粗针活检时钙化灶清除率大于或等于90%、累及的终末导管小叶单位小于或等于2个且不存在细胞学异型性或坏死的女性，漏诊癌症的可能性可能小于5%。
Zotero 插件